Presentation is loading. Please wait.

Presentation is loading. Please wait.

CONSORT diagram. a, 5 had a major treatment violation (3 refused and 2 received wrong treatment) but were included in the analyses; b, 4 had a major treatment.

Published bySiri Frantzen Modified over 5 years ago

Similar presentations

Presentation on theme: "CONSORT diagram. a, 5 had a major treatment violation (3 refused and 2 received wrong treatment) but were included in the analyses; b, 4 had a major treatment."— Presentation transcript:

1 CONSORT diagram. a, 5 had a major treatment violation (3 refused and 2 received wrong treatment) but were included in the analyses; b, 4 had a major treatment violation (2 refused and 2 received wrong treatment) but were included in the analyses. CONSORT diagram. a, 5 had a major treatment violation (3 refused and 2 received wrong treatment) but were included in the analyses; b, 4 had a major treatment violation (2 refused and 2 received wrong treatment) but were included in the analyses. AUA, American Urological Association. James R. Marshall et al. Cancer Prev Res 2011;4: ©2011 by American Association for Cancer Research

Download ppt "CONSORT diagram. a, 5 had a major treatment violation (3 refused and 2 received wrong treatment) but were included in the analyses; b, 4 had a major treatment."

Similar presentations

Odds ratios for change in PD from earliest mammogram within levels of earliest PD. No evidence for an interaction of earliest PD and change in PD on breast.

Odds ratios for change in PD from earliest mammogram within levels of earliest PD. No evidence for an interaction of earliest PD and change in PD on breast.
Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
IL-1β differentially regulates CXCL5 and CXCL8 protein secretion in NHTBE and NSCLC cells. IL-1β differentially regulates CXCL5 and CXCL8 protein secretion.

IL-1β differentially regulates CXCL5 and CXCL8 protein secretion in NHTBE and NSCLC cells. IL-1β differentially regulates CXCL5 and CXCL8 protein secretion.
IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.

IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.
25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.
Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.
IL32 prompts cell activation and cancer-related pathways.

IL32 prompts cell activation and cancer-related pathways.
Effect of supplementation with SeMet or SY on plasma selenium levels in adult men. Effect of supplementation with SeMet or SY on plasma selenium levels.

Effect of supplementation with SeMet or SY on plasma selenium levels in adult men. Effect of supplementation with SeMet or SY on plasma selenium levels.
Histologic characterization of ACF, and the effects of tocopherol treatment on ACF formation, 4-HNE levels, and nitrotyrosine levels in the colon. Histologic.

Histologic characterization of ACF, and the effects of tocopherol treatment on ACF formation, 4-HNE levels, and nitrotyrosine levels in the colon. Histologic.
Distribution of informative SNPs with LOH (black bars) on each chromosome (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome)

Distribution of informative SNPs with LOH (black bars) on each chromosome (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome)
ROC curve for separating advanced stages (advanced BE and EA) versus early stages (BE or BE instability) using total genome-wide LOH [area under the curve.

ROC curve for separating advanced stages (advanced BE and EA) versus early stages (BE or BE instability) using total genome-wide LOH [area under the curve.
Number of 0.5-Mb windows with chromosome lesions that reached statistical significance across patients in early (BE early and BE instability) and late.

Number of 0.5-Mb windows with chromosome lesions that reached statistical significance across patients in early (BE early and BE instability) and late.
NICD1 immunohistochemical staining in normal and tumor tissue.

NICD1 immunohistochemical staining in normal and tumor tissue.
Possible sites of action of aspirin in the prevention of colorectal cancer. Possible sites of action of aspirin in the prevention of colorectal cancer.

Possible sites of action of aspirin in the prevention of colorectal cancer. Possible sites of action of aspirin in the prevention of colorectal cancer.
Differences in breast cancer risk between the 75th and the 25th percentile of urinary phytoestrogen excretion, by race-ethnic group, Multiethnic Cohort.

Differences in breast cancer risk between the 75th and the 25th percentile of urinary phytoestrogen excretion, by race-ethnic group, Multiethnic Cohort.
CAPP2: Time to first colorectal cancer in those randomized to aspirin compared with those randomized to the aspirin placebo. CAPP2: Time to first colorectal.

CAPP2: Time to first colorectal cancer in those randomized to aspirin compared with those randomized to the aspirin placebo. CAPP2: Time to first colorectal.
CONSORT flow diagram for the randomised controlled trial of the iCBT-MDD programme for people with diabetes. iCBT-MDD, internet-based cognitive behaviour.

CONSORT flow diagram for the randomised controlled trial of the iCBT-MDD programme for people with diabetes. iCBT-MDD, internet-based cognitive behaviour.
Expression of cGMP signaling components in polyps.

Expression of cGMP signaling components in polyps.
Changes in the ratio of (EPA+DHA):AA in the breast triacylglyceride compartment. Changes in the ratio of (EPA+DHA):AA in the breast triacylglyceride compartment.

Changes in the ratio of (EPA+DHA):AA in the breast triacylglyceride compartment. Changes in the ratio of (EPA+DHA):AA in the breast triacylglyceride compartment.
TFAP2A interacts with HIF-1α and regulates VEGF expression and cell proliferation. TFAP2A interacts with HIF-1α and regulates VEGF expression and cell.

TFAP2A interacts with HIF-1α and regulates VEGF expression and cell proliferation. TFAP2A interacts with HIF-1α and regulates VEGF expression and cell.

Similar presentations

Ads by Google